Long-term effectiveness of aripiprazole once monthly on functioning and quality of life in schizophrenia: results of year 2 of the ReLiAM study
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Long-term effectiveness of aripiprazole once monthly on functioning and quality of life in schizophrenia: results of year 2 of the ReLiAM study ; volume:24 ; number:1 ; day:14 ; month:11 ; year:2024 ; pages:1-9 ; date:12.2024
BMC psychiatry ; 24, Heft 1 (14.11.2024), 1-9, 12.2024
- Urheber
-
Roy, Marc-André
Therrien, François
Boucher, Matthieu
Oluboka, Oloruntoba
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12888-024-06240-x
- URN
-
urn:nbn:de:101:1-2502040922322.748384893317
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:29 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Roy, Marc-André
- Therrien, François
- Boucher, Matthieu
- Oluboka, Oloruntoba
- SpringerLink (Online service)
Ähnliche Objekte (12)
Improvement of functioning in patients with schizophrenia: real-world effectiveness of aripiprazole once-monthly (REACT study)
Effectiveness of aripiprazole once-monthly in schizophrenia patients pretreated with oral aripiprazole: a 6-month, real-life non-interventional study
Correction to: Effectiveness of aripiprazole once-monthly in schizophrenia patients pretreated with oral aripiprazole: a 6-month, real-life non-interventional study
Cost-Utility Analysis of Lurasidone Versus Aripiprazole in Adults with Schizophrenia
Symptomatic, functional and quality of life measures of remission in 194 outpatients with schizophrenia followed naturalistically in a 6-month, non-interventional study of aripiprazole once-monthly
Once-Monthly Long-Acting Injectable Aripiprazole for the Treatment of Patients with Schizophrenia and Co-occurring Substance Use Disorders: A Multicentre, Observational Study
Long-Acting Injectable Antipsychotics in Schizophrenia: Literature Review and Practical Perspective, with a Focus on Aripiprazole Once-Monthly
Long-term effect of aripiprazole lauroxil on health-related quality of life in patients with schizophrenia
Effectiveness and safety of aripiprazole oral solution in the acute treatment of schizophrenia in Chinese patients
Treatment with aripiprazole once-monthly injectable formulation is effective in improving symptoms and global functioning in schizophrenia with and without comorbid substance use – a post hoc analysis of the ReLiAM study
Treatment persistence with aripiprazole once monthly: a 4-year follow-up
Correction to: Once‑Monthly Long‑Acting Injectable Aripiprazole for the Treatment of Patients with Schizophrenia and Co‑occurring Substance Use Disorders: A Multicentre, Observational Study
Improvement of functioning in patients with schizophrenia: real-world effectiveness of aripiprazole once-monthly (REACT study)
Effectiveness of aripiprazole once-monthly in schizophrenia patients pretreated with oral aripiprazole: a 6-month, real-life non-interventional study
Correction to: Effectiveness of aripiprazole once-monthly in schizophrenia patients pretreated with oral aripiprazole: a 6-month, real-life non-interventional study
Cost-Utility Analysis of Lurasidone Versus Aripiprazole in Adults with Schizophrenia
Symptomatic, functional and quality of life measures of remission in 194 outpatients with schizophrenia followed naturalistically in a 6-month, non-interventional study of aripiprazole once-monthly
Once-Monthly Long-Acting Injectable Aripiprazole for the Treatment of Patients with Schizophrenia and Co-occurring Substance Use Disorders: A Multicentre, Observational Study
Long-Acting Injectable Antipsychotics in Schizophrenia: Literature Review and Practical Perspective, with a Focus on Aripiprazole Once-Monthly
Long-term effect of aripiprazole lauroxil on health-related quality of life in patients with schizophrenia
Effectiveness and safety of aripiprazole oral solution in the acute treatment of schizophrenia in Chinese patients
Treatment with aripiprazole once-monthly injectable formulation is effective in improving symptoms and global functioning in schizophrenia with and without comorbid substance use – a post hoc analysis of the ReLiAM study
Treatment persistence with aripiprazole once monthly: a 4-year follow-up
Correction to: Once‑Monthly Long‑Acting Injectable Aripiprazole for the Treatment of Patients with Schizophrenia and Co‑occurring Substance Use Disorders: A Multicentre, Observational Study
Improvement of functioning in patients with schizophrenia: real-world effectiveness of aripiprazole once-monthly (REACT study)
Effectiveness of aripiprazole once-monthly in schizophrenia patients pretreated with oral aripiprazole: a 6-month, real-life non-interventional study
Correction to: Effectiveness of aripiprazole once-monthly in schizophrenia patients pretreated with oral aripiprazole: a 6-month, real-life non-interventional study
Cost-Utility Analysis of Lurasidone Versus Aripiprazole in Adults with Schizophrenia
Symptomatic, functional and quality of life measures of remission in 194 outpatients with schizophrenia followed naturalistically in a 6-month, non-interventional study of aripiprazole once-monthly
Once-Monthly Long-Acting Injectable Aripiprazole for the Treatment of Patients with Schizophrenia and Co-occurring Substance Use Disorders: A Multicentre, Observational Study
Long-Acting Injectable Antipsychotics in Schizophrenia: Literature Review and Practical Perspective, with a Focus on Aripiprazole Once-Monthly
Long-term effect of aripiprazole lauroxil on health-related quality of life in patients with schizophrenia
Effectiveness and safety of aripiprazole oral solution in the acute treatment of schizophrenia in Chinese patients
Treatment with aripiprazole once-monthly injectable formulation is effective in improving symptoms and global functioning in schizophrenia with and without comorbid substance use – a post hoc analysis of the ReLiAM study
Treatment persistence with aripiprazole once monthly: a 4-year follow-up